Celanese (CE) Live Stock Price, Key Metrics, & History

Jump To Section

$

9

8

7

6

5

4

3

2

1

0

0

9

8

7

6

5

4

3

2

1

0

0

.

9

8

7

6

5

4

3

2

1

0

0

9

8

7

6

5

4

3

2

1

0

0

-$0.35 (-0.78%)Past DayPrev Close: $45.44Today's Volume:

9

8

7

6

5

4

3

2

1

0

0

9

8

7

6

5

4

3

2

1

0

0

9

8

7

6

5

4

3

2

1

0

0

,

9

8

7

6

5

4

3

2

1

0

0

Toggle RSI

About

Celanese (CE) Business Model and Operations Summary

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Key Insights

Celanese (CE) Stock Information & Key Business Metrics

Market Cap
$166.17 Million
Average Daily Volume
1,887,625 Shares
52-Week Range
$1.73-$11.41
Free Cash Flow
$1.02 Billion
Total Outstanding Shares
109.50 Million Shares
Free Float
109.05 Million Shares (99.6% Outstanding)
CEO
David A. Happel
Total Employees
12,163
Current Dividend
$0.03 Per Share Quarterly
IPO Date
January 21, 2005
Headquarters
222 W. Las Colinas Blvd., Suite 900n, Irving, TX, 75039-5421

Financial Highlights

Celanese (CE) Key Financial Metrics

Earnings Reports

Expected vs. Actual Quarterly Earnings-Per-Share & Revenue

Short Volume

Daily short volume activity identifies short-term trading pressure and potential price volatility

Short Interest

Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential

Revenue Breakdown

Distribution of revenue across unique business segments & geographies

Cash Flow Statement

Income Statement

Balance Sheet

Historical Stock Splits

Historical Dividends

Current dividend: $0.03 Per Share Quarterly

CE Articles From Financhle

Recent analysis, market insights, and in-depth coverage of CE from analysts at Financhle

S&P 500 Rebalance March 2025: DoorDash Joins, Coinbase Snubbed - Inside SPY’s Sector Shifts and Financial Shake-UpDoorDash, Expand Energy, and two additional companies leap into the S&P 500 while Coinbase and Robinhood miss out - uncover the financial drivers and sector twists reshaping SPY this quarter.
FinanchleMarch 11, 2025

Recent Headlines From The Web

Latest news, press releases, and media coverage about CE from trusted financial sources

Related Companies

Publicly traded companies similar to Celanese (CE)

Boost your savings and earn 3.95% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.